71.

(Once amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding at least a first peptide consisting of 9 to 10 amino acid residues, wherein said first encoded peptide comprises a motif selected from the group consisting of: (a) a Pro residue at position 2 and a Leu residue at the C-terminal position; (b) a Pro residue at position 2 and a Phe residue at the C-terminal position; (c) a Pro residue at position 2 and a Met residue at the Cterminal position; (d) a Pro residue at position 2 and a Trp residue at the C-terminal position; (e) a Pro residue at position 2 and an Ala residue at the Oterminal position; and (f) a Pro residue at position 2 and a Tyr residue at the C-terminal position; wherein said first encoded peptide binds to at least two of the HLA molecules encoded by B0701, B3501, B3502, B3503, B5101, B5301, B5401, and CW0601 alleles; and wherein said first encoded peptide is from an HIV antigen, an HBV antigen, an HCV antigen, an HPV antigen, or a Plasmodium falciparum antigen.

74. (Once amended) The nucleic acid molecule of claim 71, wherein said first encoded peptide binds to at least three of said HLA molecules.

- 75. (Once amended) The nucleic acid molecule of claim 74, wherein said first encoded peptide binds to more than three of said HLA molecules.
- 76. (Once amended) The nucleic acid molecule of claim 71, wherein said nucleotide sequence further encodes a second peptide which is a CTL epitope.

Please add the following new claims \$9-111.

(New) The nucleic acid molecule of claim 71, wherein said first encoded peptide is from an HIV antigen.

80. (New) The nucleic acid molecule of claim 71, wherein said first encoded peptide is from an HBV antigen.

44

(New) The nucleic acid molecule of claim 71, wherein said first encoded peptide is from an HCV antigen.

82. (New) The nucleic acid molecule of claim 71, wherein said first encoded peptide is from an HPV antigen.

(New) The nucleic acid molecule of claim 71, wherein said first encoded peptide is from a Plasmodium falciparum antigen.

(New) The nucleic acid molecule of claim 71, wherein said nucleotide sequence further encodes an HTL epitope.

(New) The nucleic acid molecule of claim 71, wherein said nucleotide sequence further encodes an mRNA stabilization sequence.

(New) The nucleic acid molecule of claim 71, wherein said nucleotide sequence further encodes a leader/signal sequence.

(New) The nucleic acid molecule of claim 71, wherein said nucleotide sequence further encodes an endoplasmic reticulum retention sequence.

(New) The nucleic acid molecule of claim 71, wherein said first encoded peptide comprises the motif: a Pro residue at position 2 and a Leu residue at the C-terminal position.

(New) The nucleic acid molecule of claim 88, wherein said first encoded peptide binds to at least three of said HLA molecules.

90. (New) The nucleic acid molecule of claim 88, wherein said nucleotide sequence further encodes an HTL epitope.

(New) The nucleic acid molecule of claim 88, wherein said nucleotide sequence further encodes a second peptide which is a CTL epitope.

(New) The nucleic acid molecule of claim 71, wherein said first encoded peptide comprises the motif: a Pro residue at position 2 and a Phe at the C-terminal position.

(New) The nucleic acid molecule of claim 92, wherein said first encoded peptide binds to at least three of said HLA molecules.

(New) The nucleic acid molecule of claim 92, wherein said nucleotide sequence further encodes an HTL epitope.

(New) The nucleic acid molecule of claim 92, wherein said nucleotide sequence further encodes a second peptide which is a CTL epitope.

(New) The nucleic acid molecule of claim 71, wherein said first encoded peptide comprises the motif: a Pro residue at position 2 and a Met residue at the C-terminal position.

(New) The nucleic acid molecule of claim 96, wherein said first encoded peptide binds to at least three of said HLA molecules.

98. (New) The nucleic acid molecule of claim 96, wherein said nucleotide sequence further encodes an HTL epitope.

99% (New) The nucleic acid molecule of claim 96, wherein said nucleotide sequence further encodes a second peptide which is a CTL epitope.

100. (New) The nucleic acid molecule of claim 71, wherein said first encoded peptide comprises the motif: a Pro residue at position 2 and a Trp residue at the C-terminal position.

10.1. (New) The nucleic acid molecule of claim 100, wherein said first encoded peptide binds to at least three of said HLA molecules.

10%. (New) The nucleic acid molecule of claim 100, wherein said nucleotide sequence further encodes an HTL epitope.

103 (New) The nucleic acid molecule of claim 100, wherein said nucleotide sequence further encodes a second peptide which is a CTL epitope.

104. (New) The nucleic acid molecule of claim 71, wherein said first encoded peptide comprises the motif: a Pro residue at position 2 and an Ala residue at the C-terminal position.

105. (New) The nucleic acid molecule of claim 104, wherein said first encoded peptide binds to at least three of said HLA molecules.

106: (New) The nucleic acid molecule of claim 104, wherein said nucleotide sequence further encodes an HTL epitope.

107. (New) The nucleic acid molecule of claim 104, wherein said nucleotide sequence further encodes a second peptide which is a CTL epitope.

108: (New) The nucleic acid molecule of claim 71, wherein said first encoded peptide comprises the motif: a Pro residue at position 2 and a Tyr residue at the C-terminal position.

109. (New) The nucleic acid molecule of claim 108, wherein said first encoded peptide binds to at least three of said HLA molecules.

170. (New) The nucleic acid molecule of claim 108, wherein said nucleotide sequence further encodes an HTL epitope.

(New) The nucleic acid molecule of claim 108, wherein said nucleotide sequence

further encodes a second peptide which is a CTL epitope.